Clinical epidemiology of cardiac disease in dialysis patients: Left ventricular hypertrophy, ischemic heart disease, and cardiac failure

被引:151
作者
Foley, RN [1 ]
机构
[1] Hennepin Cty Med Ctr, Nephrol Analyt Serv, Minneapolis, MN 55404 USA
关键词
D O I
10.1046/j.1525-139X.2003.160271.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Patients with end-stage renal disease (ESRD) are at extreme cardiovascular risk. At least half of all patients starting dialysis therapy have overt cardiovascular disease (CVD). In addition, recent studies suggest annual incidence rates for new-onset cardiac failure, peripheral vascular disease, ischemic heart disease (IHD), and stroke of approximately 7%, 7%, 5%, and 1%, respectively. High-level exposure to traditional risk factors, such as smoking and dyslipidemia, hemodynamic overload factors, such as anemia and hypertension, and a myriad of metabolic factors related to uremia are all likely to play a role. There has been explosive growth in observational studies and a heartening, if less dramatic, increase in risk factor intervention trials, suggesting that risk factor modification can lead to meaningful benefit.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 74 条
[1]  
[Anonymous], 1992, Am J Kidney Dis, V20, P32
[2]   Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations [J].
Asmar, R ;
Rudnichi, A ;
Blacher, J ;
London, GM ;
Safar, ME .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (02) :91-97
[3]  
Baigent Colin, 2001, Journal of the American Society of Nephrology, V12, p190A
[4]   PROGNOSIS AFTER 1ST MYOCARDIAL-INFARCTION - COMPARISON OF Q-WAVE AND NON-Q-WAVE MYOCARDIAL-INFARCTION IN THE FRAMINGHAM HEART-STUDY [J].
BERGER, CJ ;
MURABITO, JM ;
EVANS, JC ;
ANDERSON, KM ;
LEVY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (12) :1545-1551
[5]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[6]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[7]   Relationship of dose of hemodialysis and cause-specific mortality [J].
Bloembergen, WE ;
Stannard, DC ;
Port, FK ;
Wolfe, RA ;
Pugh, JA ;
Jones, CA ;
Greer, JW ;
Golper, TA ;
Held, PJ .
KIDNEY INTERNATIONAL, 1996, 50 (02) :557-565
[8]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[9]  
Bostom AG, 1999, J AM SOC NEPHROL, V10, P891
[10]   Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis [J].
Chan, CT ;
Floras, JS ;
Miller, JA ;
Richardson, RMA ;
Pierratos, A .
KIDNEY INTERNATIONAL, 2002, 61 (06) :2235-2239